15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22

      discussion
      a , 1 ,
      F1000Research
      F1000 Research Limited
      CHEERS 22, ISPOR, ICER, pseudoscience, I-QALY

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          One of the more unfortunate features of health technology assessment is the tenacity with which leaders in the field and organizations such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Institute for Clinical and Economic Review (ICER) cling to an evaluation framework that fails to meet the standards of normal science. Believers subscribe to a meme that is clearly non-science (metaphysics and pseudoscience) and one that should have been discarded over 30 years ago. Certainly, subscribing to an impossible belief is not unusual; indeed it may make the belief that much stronger. Yet the meme is non-sustainable; it is also pointless as the economic evaluation claims are non-evaluable. There is no acknowledgement of the standards of normal science or the limitations imposed by the axioms of fundamental measurement. The purpose of this commentary is to make the case that the recent release of the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 22) checklist is misleading; CHEERS 22 fails to address the manifest deficiencies in the approach to economic evaluations endorsed by ISPOR and ICER. Instead, it continues to promote economic evaluations in healthcare that invent evidence and non-empirically evaluable value claims. Given the widespread publicity that has accompanied the release of CHEERS 22, the purpose of this commentary is to detail the deficiencies in CHEERS 22 and propose an alternative framework for economic evaluation in health care to meet the information needs of formulary committees. This means abandoning the standards for economic evaluations that have dominated health technology assessment for 30 years, notably the key role assigned to the mathematically impossible quality adjusted life year (QALY). The proposed new start recommends single attribute evaluable value claims that meet ratio or interval measurement standards and are supported by evaluation protocols.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Article: not found

          On the Theory of Scales of Measurement.

          S. Stevens (1946)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.

            Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces the previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, and the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as healthcare, public health, education, and social care). This Explanation and Elaboration Report presents the new CHEERS 2022 28-item checklist with recommendations and explanation and examples for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer-reviewed journals and the peer reviewers and editors assessing them for publication. Nevertheless, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, given that there is an increasing emphasis on transparency in decision making.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found
              Is Open Access

              United States Valuation of EQ-5D-5L Health States Using an International Protocol

                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: MethodologyRole: Writing – Original Draft Preparation
                Journal
                F1000Res
                F1000Res
                F1000Research
                F1000 Research Limited (London, UK )
                2046-1402
                28 February 2022
                2022
                : 11
                : 248
                Affiliations
                [1 ]College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA
                [1 ]JB Medical Ltd, Sudbury, UK
                [1 ]Director, Mediconomics, Hanover, Germany
                Author notes

                Competing interests: PCL is Director, Maimon Research LLC, a boutique consulting company in Tucson AZ, and is an Advisory Board Member and Consultant to the Institute for Patient Access and Affordability, a program of Patients Rising.

                Competing interests: No competing interests were disclosed.

                Competing interests: No competing interests were disclosed.

                Author information
                https://orcid.org/0000-0002-9092-1246
                Article
                10.12688/f1000research.109389.1
                8994082
                35444797
                8ae2dbb7-5f76-4aab-8cb1-b9706868b59c
                Copyright: © 2022 Langley P

                This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 February 2022
                Funding
                The author(s) declared that no grants were involved in supporting this work.
                Categories
                Opinion Article
                Articles

                cheers 22,ispor,icer,pseudoscience,i-qaly
                cheers 22, ispor, icer, pseudoscience, i-qaly

                Comments

                Comment on this article